U.S., Dec. 16 -- ClinicalTrials.gov registry received information related to the study (NCT07282587) titled 'Study of ONC206 (JZP3507) in Advanced Pheochromocytoma and Paraganglioma' on Dec. 05.
Brief Summary: This is a two-stage Phase 2 trial evaluating the efficacy and safety of ONC206 in participants with Pheochromocytoma and Paraganglioma (PCPG).
Study Start Date: Dec. 15
Study Type: INTERVENTIONAL
Condition:
Advanced Pheochromocytoma and Paraganglioma
PCPG
Intervention:
DRUG: ONC206
150 mg BID TIW
DRUG: ONC206: Dose 1
DRUG: ONC206: Dose 2
Recruitment Status: NOT_YET_RECRUITING
Sponsor: Jazz Pharmaceuticals
Published by HT Digital Content Services with permission from Health Daily Digest....